Search research articles
Contact Us
Filters
Showing results (91-100 of 134) with videos related to
Page
of 14
Sort By:
Journal of Neuro-Oncology
|
November 22, 2018
Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis
Zhong Liu, Pulin Che, Juan J Mercado, et al.
Cell Reports. Medicine
|
July 2, 2024
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
May 3, 2025
Inhibition of the RNA Regulator HuR Mitigates Spinal Cord Injury by Potently Suppressing Post-Injury Neuroinflammation
Mohammed Amir Husain, Reed Smith, Robert E Sorge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma
Adam N Mamelak, Steven Rosenfeld, Richard Bucholz, et al.
Neuro-Oncology
|
March 13, 2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L Burt Nabors, Karen L Fink, Tom Mikkelsen, et al.
Neuro-Oncology Advances
|
October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
Journal of Palliative Medicine
|
July 30, 2020
Implementing a Clinic-Based Telehealth Support Service (FamilyStrong) for Family Caregivers of Individuals with Grade IV Brain Tumors
J Nicholas Dionne-Odom, Grant R Williams, Paula P Warren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
David A Reardon, Karen L Fink, Tom Mikkelsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma
Martin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
AJNR. American Journal of Neuroradiology
|
May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)
Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 134) with videos related to
Sort By:
Page
of 14
Journal of Neuro-Oncology
|
November 22, 2018
Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis
Zhong Liu, Pulin Che, Juan J Mercado, et al.
Cell Reports. Medicine
|
July 2, 2024
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
May 3, 2025
Inhibition of the RNA Regulator HuR Mitigates Spinal Cord Injury by Potently Suppressing Post-Injury Neuroinflammation
Mohammed Amir Husain, Reed Smith, Robert E Sorge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma
Adam N Mamelak, Steven Rosenfeld, Richard Bucholz, et al.
Neuro-Oncology
|
March 13, 2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L Burt Nabors, Karen L Fink, Tom Mikkelsen, et al.
Neuro-Oncology Advances
|
October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
Journal of Palliative Medicine
|
July 30, 2020
Implementing a Clinic-Based Telehealth Support Service (FamilyStrong) for Family Caregivers of Individuals with Grade IV Brain Tumors
J Nicholas Dionne-Odom, Grant R Williams, Paula P Warren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
David A Reardon, Karen L Fink, Tom Mikkelsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma
Martin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
AJNR. American Journal of Neuroradiology
|
May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)
Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Page
of 14